A Clinical Trial Result Is Not Necessarily Your Result
A large genomic study being presented at the AACR Annual Meeting this April is confirming something many of us in the appendix cancer community have felt for a long time:
Goblet Cell Adenocarcinoma (GCA) is not the same disease as mucinous appendix cancer.
And if those diseases aren’t the same, we have to be careful about assuming that the same treatments (or the same clinical trial results) apply to both.
The AACR Annual Meeting & Why You Should Care
The American Association for Cancer Research Annual Meeting is one of the biggest cancer research conferences in the world. It’s where scientists and doctors share new findings – often before they’re officially published.
For rare cancers like appendix cancer, that matters. This is often where we get an early look at what researchers are learning and where treatment is headed.
This year’s meeting runs April 17–22 in San Diego, CA.
The Researchers
This is not a random multi-center study. This is a highly coordinated ecosystem study conducted by MD Anderson Cancer Center & The Shen Lab lead by Dr. John Paul Shen that combined:
- Surgeons (who treat appendix cancer daily)
- Oncologists (who run trials)
- Lab scientists (who study tumor biology)
- Computational biologists (who analyze sequencing data)
What is The Shen Lab? Focus is on appendiceal cancer genomics, CRISPR models, precision oncology Includes computational + wet lab + clinical collaborators. Explicitly works on appendiceal adenocarcinoma biology and drug targets
What this study looked at
Researchers analyzed tumor samples from 1,202 appendix cancer patients across four subtypes:
- Goblet Cell Adenocarcinoma (GCA)
- Mucinous
- Enteric-type
- Signet ring cell
They were trying to answer a simple question:
Are these actually the same disease….or are they just grouped together because they all start in the APPENDIX?
What they found (in plain terms)
They’re not the same.
In non-GCA appendix cancers, tumors are often driven by a few common mutations – especially:
- KRAS (about 73%)
- GNAS (about 36%)
GCA looks very different.
- No single mutation shows up in more than 20% of cases
- Only about 10% of GCA tumors have KRAS mutations
- The most common mutation is in a gene called ZFP36L2 (18%)
ZFP36L2 appears to act like a brake on tumor growth. When researchers removed it in lab models, tumors grew faster and activated multiple cancer-related pathways. That suggests GCA may develop and behave differently than other appendix cancers, though more research is still needed.
The outcomes reflected that difference:
- GCA patients had a median survival of about 95 months
- For non-GCA patients, median survival wasn’t reached during the study period
- Overall, GCA patients had about 3.5 times higher risk of death
You can read the technical abstract on the AARC website here: Goblet cell appendiceal adenocarcinoma is molecularly distinct from other histologic subtypes: Insights from large-scale genomic, transcriptomic, and organoid modeling.
What this means when you are looking at treatment:
For a long time, appendix cancer has been treated like one disease — mostly because it’s rare, and grouping patients together made research easier.
But this study shows pretty clearly that these cancers don’t just look different — they behave differently.
And that matters when you’re trying to make decisions.
A trial can show a positive result overall….even if that benefit came from only one subtype.
Or it can look negative overall….even if one group of patients actually did benefit.
Without seeing the data broken down by subtype, you’re looking at an average that may not reflect your reality.
A treatment can look effective – or ineffective – based on averages that combine very different diseases.
What this means for patients
When you’re looking at a treatment or a clinical trial, it’s worth asking:
- Were patients like me included in this study?
- Do we know how my specific subtype responded?
- Or am I looking at an average across very different diseases?
Those answers can change how you interpret the data.
Where this leaves us
If you have GCA, this helps explain why things can feel a little unclear sometimes. A lot of the data out there wasn’t built specifically for your disease.
If you have a different type of appendix cancer, it’s just as important to be careful with how you interpret results – especially when different subtypes are mixed together.
Either way, this is really what it comes down to:
You’re not just “an appendix cancer patient.”
You have a specific type and that matters more than most studies have accounted for.
It’s completely reasonable to ask:
Was this actually studied in patients like me?
That’s not being difficult.
That’s making sure the information you’re using actually fits your situation.
This post is for informational purposes only and is not medical advice. Please consult your oncologist regarding your specific situation.
Leave a Reply